NasdaqGS:CLVS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. More Details


Snowflake Analysis

Limited growth with imperfect balance sheet.


Similar Companies

Share Price & News

How has Clovis Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLVS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CLVS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

3.5%

CLVS

1.9%

US Biotechs

2.1%

US Market


1 Year Return

-64.2%

CLVS

21.2%

US Biotechs

19.8%

US Market

Return vs Industry: CLVS underperformed the US Biotechs industry which returned 21.1% over the past year.

Return vs Market: CLVS underperformed the US Market which returned 19.7% over the past year.


Shareholder returns

CLVSIndustryMarket
7 Day3.5%1.9%2.1%
30 Day-16.0%6.5%8.1%
90 Day-14.5%7.1%6.0%
1 Year-64.2%-64.2%23.3%21.2%22.5%19.8%
3 Year-92.9%-92.9%21.7%15.4%46.5%36.8%
5 Year-86.7%-86.7%14.9%7.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is Clovis Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clovis Oncology undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Clovis Oncology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Clovis Oncology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

25.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLVS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLVS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLVS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLVS's revenue (23.9% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: CLVS's revenue (23.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLVS is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Clovis Oncology performed over the past 5 years?

-2.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLVS is currently unprofitable.

Growing Profit Margin: CLVS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLVS is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare CLVS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: CLVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Clovis Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CLVS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CLVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLVS has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CLVS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 12.2% each year.


Next Steps

Dividend

What is Clovis Oncology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLVS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLVS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Patrick Mahaffy (57 yo)

11.58yrs

Tenure

US$6,907,470

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. on April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD6.91M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Patrick Mahaffy
Co-Founder11.58yrsUS$6.91m1.1%
$ 4.3m
Gillian Ivers-Read
Co-Founder11.58yrsUS$2.64m0.24%
$ 953.7k
Daniel Muehl
Executive VP & CFO4.67yrsUS$3.58m0.039%
$ 151.7k
Paul Gross
Executive VP4.83yrsUS$3.59m0.034%
$ 133.7k
Lindsey Rolfe
Executive VP of Clinical5.25yrsUS$2.69m0.060%
$ 234.5k
Breanna Burkart
Vice President of Investor Relations & Corporate Communications4.17yrsno datano data
Ann Bozeman
Executive Vice President of Human Resources4.17yrsno datano data
Anna Sussman
Vice President of Investor Relationsno datano datano data

4.8yrs

Average Tenure

56yo

Average Age

Experienced Management: CLVS's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Patrick Mahaffy
Co-Founder11.58yrsUS$6.91m1.1%
$ 4.3m
Paul Klingenstein
Independent Director11.58yrsUS$359.90k0.067%
$ 263.4k
Brian Atwood
Independent Director11.83yrsUS$369.31k0.066%
$ 259.0k
Edward McKinley
Independent Director11.83yrsUS$369.90k0.28%
$ 1.1m
James Blair
Independent Director11.83yrsUS$369.90k0.072%
$ 282.1k
Ginger Graham
Independent Chairman1.42yrsUS$374.36k0%
$ 0
Thorlef Spickschen
Independent Director11.83yrsUS$357.40k0.066%
$ 258.3k
Keith Flaherty
Independent Director7.83yrsUS$354.90k0%
$ 0
Richard Fair
Independent Director2.08yrsUS$357.40k0%
$ 0
Robert Azelby
Independent Director2.08yrsUS$354.90k0%
$ 0

11.6yrs

Average Tenure

64yo

Average Age

Experienced Board: CLVS's board of directors are seasoned and experienced ( 11.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.1%.


Top Shareholders

Company Information

Clovis Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clovis Oncology, Inc.
  • Ticker: CLVS
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$392.136m
  • Shares outstanding: 88.32m
  • Website: https://www.clovisoncology.com

Number of Employees


Location

  • Clovis Oncology, Inc.
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLVSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2011
C6ODB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011
C6OXTRA (XETRA Trading Platform)YesCommon StockDEEURNov 2011

Biography

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offer...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 23:24
End of Day Share Price2020/11/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.